Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
COMPLETED
NCT03694275
PHASE2

A Multicenter, Open-label, Pilot Study of Soticlestat (TAK-935/OV935) in Participants With 15Q Duplication Syndrome (Dup 15q) or Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder (ARCADE STUDY)

Sponsor: Takeda

View on ClinicalTrials.gov

Summary

The purpose of this study is to investigate the effect of soticlestat on the frequency of motor seizures for participants with Dup15q or CDD during the Maintenance Period.

Official title: A Multicenter, Open-label, Pilot Study of TAK-935 (OV935) in Patients With 15Q Duplication Syndrome or CDKL5 Deficiency Disorder (ARCADE Study)

Key Details

Gender

All

Age Range

2 Years - 55 Years

Study Type

INTERVENTIONAL

Enrollment

20

Start Date

2018-09-10

Completion Date

2020-07-31

Last Updated

2026-09-10

Healthy Volunteers

No

Interventions

DRUG

Soticlestat

TAK-935 tablets

Locations (8)

UCLA

Los Angeles, California, United States

Research Institute Children's Hospital Colorado

Aurora, Colorado, United States

Center for Rare Neurological Diseases

Norcross, Georgia, United States

Center for Rare Neurological Diseases (CRND)--Massachusetts General Hospital

Boston, Massachusetts, United States

Boston Children's Hospital Translational Neuroscience Center

Boston, Massachusetts, United States

Minnesota Epilepsy Group, P.A.

Saint Paul, Minnesota, United States

New York University (NYU)

New York, New York, United States

Columbia University Medical Center

New York, New York, United States